© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Mayo Clinic
Latest from Mayo Clinic
Erenumab Shows No Increased Hypertension Risk for Patients With Migraine
October 04, 2021
Article
During the double-blind treatment phase, rates of hypertension AEs were low for the placebo and erenumab 70- and 140-mg treatment groups, as well as during open-label erenumab treatment.
Eculizumab Provides Long-Term Effective Management of NMOSD
September 26, 2021
Article
Between PREVENT baseline and end, mean EDSS and Hauser Ambulation Index scores improved with eculizumab (Soliris; Alexion) monotherapy and deteriorated with placebo alone.
NeuroVoices: Sean Pittock, MD, on Improving Treatment Optimization, Clinical Pipeline of NMOSD
September 01, 2021
Article
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed unmet needs of care for patients with neuromyelitis optica spectrum disorder.
Assessing the State of NMOSD Treatment Following Treatment Influx
August 29, 2021
Article
The director of Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided context on challenges within the NMOSD space and what’s next following the first-approved therapies.
Greatest Strides Made in NMOSD Care: Sean Pittock, MD
August 26, 2021
Video
The director of Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the most notable recent advances that has propelled care for patients with NMOSD.
Critical Aspects of NMOSD Clinical Care: Brian G. Weinshenker, MD
August 20, 2021
Video
The professor of neurology at the Mayo Clinic College of Medicine highlighted the importance of the diagnostic process and implementing an early treatment regimen for patients with NMOSD.